Pages that link to "Q38738795"

The following pages link to Clinical pharmacokinetics of terbinafine (Lamisil). (Q38738795):

Displaying 41 items.

• Melanized Fungi in Human Disease (Q24633163) (← links)
• Terbinafine. An update of its use in superficial mycoses (Q28370491) (← links)
• Determination of terbinafine in tissues (Q30881715) (← links)
• Systemic antifungal therapy (Q31825121) (← links)
• Tinea capitis (Q33916883) (← links)
• Terbinafine, a unique oral antifungal: current perceptions (Q34004695) (← links)
• Update on terbinafine with a focus on dermatophytoses (Q34620230) (← links)
• The efficacy and safety of terbinafine in children (Q35211961) (← links)
• Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses (Q35312015) (← links)
• Therapeutic options in the treatment of tinea capitis (Q35680563) (← links)
• Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin (Q35680566) (← links)
• Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease (Q35816296) (← links)
• Current use of anti-infectives in dermatology (Q36233506) (← links)
• Drug metabolite profiling and elucidation of drug-induced hepatotoxicity (Q36835826) (← links)
• Terbinafine: a pharmacological and clinical review (Q37623829) (← links)
• Pharmacokinetics of newer drugs in patients with renal impairment (Part I). (Q37724345) (← links)
• Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis (Q37750488) (← links)
• Diagnosis and treatment of dermatophytosis in dogs and cats.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. (Q39314328) (← links)
• Terbinafine inhibits oral squamous cell carcinoma growth through anti‐cancer cell proliferation and anti‐angiogenesis (Q39544454) (← links)
• Physiologically based pharmacokinetic model for terbinafine in rats and humans (Q39652193) (← links)
• Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites (Q39781003) (← links)
• Antifungal agents: an overview. Part II. (Q40449449) (← links)
• Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? (Q40598112) (← links)
• Pharmacokinetic optimisation of oral antifungal therapy (Q40791120) (← links)
• Kinetics and spectrum of activity of oral antifungals: the therapeutic implications (Q40817808) (← links)
• Terbinafine: an update (Q41674270) (← links)
• Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development (Q41740968) (← links)
• Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds (Q41820962) (← links)
• Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts (Q42548382) (← links)
• Evaluation of the disk-diffusion method to determine the in vitro efficacy of terbinafine against subcutaneous and superficial mycoses agents. (Q42949926) (← links)
• Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial (Q43572241) (← links)
• New approaches to the diagnosis and management of onychomycosis. International Symposium, Monaco, April 1-2, 1993. (Q43881209) (← links)
• In-vitro distribution of terbinafine in rat and human blood (Q43888736) (← links)
• Development of a new medium useful for the recovery of dermatophytes from clinical specimens by minimizing the carryover effect of antifungal agents (Q43951541) (← links)
• Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD? (Q47120744) (← links)
• Correlation of invitro susceptibility based on MICs and mutations with clinical response to terbinafine in patients with tinea corporis/cruris (Q57052030) (← links)
• Antimycotics (Q59650052) (← links)
• Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption (Q77974422) (← links)
• Terbinafine pharmacokinetics after single dose oral administration in the dog (Q84157634) (← links)
• Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches (Q90750811) (← links)
• A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis (Q93126474) (← links)